Letters to the Editor

Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial

Service and Central Laboratory of Hematology, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne, Switzerland; Service of Hematology and Laboratory of Hematology, Institut Central des Hôpitaux, Hôpital du Valais, Av. du Grand-Champsec 86, CH-1951 Sion, Switzerland; University of Lausanne, Lausanne
Division of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne
Service and Central Laboratory of Hematology, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne
Division of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne
University of Lausanne, Lausanne, Switzerland; Division of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne
Service and Central Laboratory of Hematology, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne, Switzerland; University of Lausanne, Lausanne
University of Lausanne, Lausanne, Switzerland; Division of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne
Haematologica Early view Sep 8, 2022 https://doi.org/10.3324/haematol.2022.281221